The pathology causing progressive aphasia is typically a variant of frontotemporal lobar degeneration, especially with ubiquitin-positive inclusions (FTLD-U). Less commonly the underlying pathology is Alzheimer disease (AD).
Speech and language impairments can be the most prominent presenting symptoms of a neurodegenerative disease. The term primary progressive aphasia (PPA) 1 is one of the labels used to classify patients when there is a prominent and progressive impairment of language without initial dementia. The term PPA captures patients whose language diffi-culties can be characterized by agrammatic and nonfluent speech, prominent anomia, fluent aphasia with comprehension deficits, or a combination or blurring of distinctions among all three features. There are also other well-publicized classification schemes. [2] [3] [4] [5] [6] [7] In our recent clinicopathologic and imaging study of PPA and apraxia of speech, 2 we demonstrated that nonfluent aphasia with apraxia of speech was associated with atrophy of the premotor and posterior inferior frontal cortices, whereas temporal lobe atrophy correlated with progressive aphasia with "fluent" speech output. The majority of our subjects with fluent aphasia had a pathologic diagnosis of frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes (FTLD-U). 2 None of our cases had a pathologic diagnosis of Alzheimer disease (AD), 8 which may have been because of our strict inclusion criteria. Two recent reports, however, demonstrated that a significant number of cases of progressive aphasia had AD pathology at postmortem. 9, 10 We therefore set out to analyze the clinicopathologic features of our cases with a progressive aphasia and AD pathology and to compare these features, plus the pattern of gray matter atrophy on MRI, with subjects with a progressive aphasia and FTLD-U pathology and with subjects with typical AD, where memory loss, not aphasia, is the cardinal feature.
METHODS Case ascertainment. The Mayo Clinic medical records database was used to identify all possible cases with prominent language impairment presenting between 1984 and 2006 by using a text word and diagnostic code search for aphasic dementia, aphasia, PPA, progressive nonfluent aphasia, semantic dementia, or apraxia of speech. A total of 5,222 subjects were identified. From these 5,222 subjects, the medical records database was used to identify the subset that had undergone a brain autopsy at the Mayo Clinic. We identified a total of 216 subjects with prominent aphasia, not necessarily meeting criteria for a diagnosis of PPA, who had an autopsy examination. The historic records of all 216 subjects were reviewed by a behavioral neurologist (K.A.J.). Of the 216 subjects, 193 were excluded because they had a structural lesion that accounted for the aphasia (e.g., left middle cerebral artery territory infarct or hemorrhage). The remaining 23 subjects with an autopsy examination had a progressive aphasia from a neurodegenerative disease. Sev-enteen of these 23 were previously published. Of the remaining 6 subjects, 5 had AD pathology and 1 had FTLD-U pathology.
All 5 subjects with aphasia and AD pathology had a volumetric head MRI scan. Five subjects with aphasia and FTLD-U pathology also had a volumetric head MRI scan. In addition, 10 subjects who had been given an antemortem clinical diagnosis of Alzheimer-type dementia, with the typical presenting feature of episodic memory loss that had pathologically confirmed AD, and had a volumetric head MRI scan were randomly selected from our Alzheimer's Disease Research Center (ADRC) Brain Bank. Therefore a total of 20 subjects, 5 with aphasia and AD pathology, 5 with aphasia and FTLD-U pathology, and 10 with typical AD type presentation and AD pathology, were used in this study.
Detailed demographic and clinical information, including the Mini-Mental State Examination (MMSE) score 11 and the Clinical Dementia Rating (CDR) sum of boxes 12 was abstracted for all 20 subjects. Speech-language pathology records of the 10 subjects with aphasia were independently reviewed by two speech-language pathologists (J.R.D. and E.A.S.), blinded to any autopsy information, to abstract detailed information regarding the speech and language examinations and to further delineate the speech and language characteristics. The speech-language results for the subjects with FTLD-U pathology have been previously published. 2 The 10 subjects with typical AD did not have speech-language pathology records but did have quantitative speech and language tests completed as part of their neuropsychological test battery. All 10 subjects with typical AD had a formal dementia evaluation by a behavioral neurologist, who did not observe any deficits in spontaneous speech in the context of the mental status examination.
All 20 subjects were also age-and sex-matched to a healthy control subject. All control subjects were prospectively recruited into the Mayo Clinic ADRC or the Alzheimer's Disease Patient Registry (ADPR) and were identified from the ADRC/ADPR database. Controls were identified as individuals who 1) were independently functioning community dwellers, 2) did not have active neurologic or psychiatric conditions, 3) had no cognitive symptoms, 4) had normal neurologic and neurocognitive examination results, and 5) were not taking any psychoactive medications in doses that would affect cognition.
Speech-language.
Data from speech-language examination of the 5 subjects with aphasia and AD pathology were tabulated and analyzed for this study. Language assessment typically included several subtests from the Minnesota Test for Differential Diagnosis of Aphasia, 13 Part V of the Token Test, 14 a letter-word fluency task, 15 and a narrative picture description (Cookie Theft) from the Boston Diagnostic Aphasia Examination. 16 Quantitative data from these tests were used to estimate severity of aphasia-in auditory comprehension, naming, repetition, reading comprehension, and writing-using a 0-to-4 scale (0 ϭ normal; 4 ϭ severe impairment) in which midpoint values (e.g., 2-3) were permitted. Independent estimates of severity by two judges (J.R.D. and E.A.S.) were within 0.5 points for 100% of the ratings. Judgments about apraxia of speech and dysarthria were derived from conversation, verbal responses during formal language assessment, and structured tasks for assessing apraxia of speech and dysarthria. 17
Neuropsychology. All data from neuropsychological testing conducted at presentation in all 20 subjects were tabulated and analyzed. Testing included executive function (Trail Making Test B 18 ); language functioning, including naming (Boston Naming test 19 ), lexical fluency (Controlled Oral Word Association Test 20 ), category/semantic fluency (animals, fruit, vegetables), and sentence comprehension (Multilingual Aphasia Examination Token 20 ); reading (Wide Range Achievement Test-3 21 or Woodcock-Johnson-Revised 22 ); learning and memory (Wechsler Memory Scale-Revised 23 ); and visuoperceptual functioning (Wechsler Adult Intelligence Scale-Revised Perceptual Organization Index 24 ). The percentile levels were derived either from norms published with the test or from Mayo Older American Normative Studies norms. 25, 26 Pathologic examination. All 20 subjects underwent standard neuropathologic examination by one of our experienced neuropathologists (J.E.P. or D.W.D.) as previously described. 27 In addition, the 15 subjects with AD pathology had brain tissue histologically analyzed with the recently described antibody TDP-43 28 to determine whether there were any pathologic features of FTLD-U, or frontotemporal lobar degeneration (FTLD) with motor neuron disease, which may be masked by the AD pathology. Semiquantitative assessment of frontal, temporal, parietal, and occipital cortex, basal nucleus, hippocampal, and substantia nigral neuronal loss was conducted in all 20 subjects using hematoxylin-andeosin stain on a 4-point grading scale as follows: 0 ϭ no neuronal loss; 1 ϭ mild neuronal loss usual associated with microvacuolation (for the cortical sections); 2 ϭ moderate neuronal loss associated with thinning of the cortical ribbon (for the cortical sections); and 3 ϭ end-stage neuronal loss associated with severe thinning of the cortical ribbon producing so-called status spongiosis (for the cortical sections). Additional pathologic features, including Braak staging 29 and National Institute on Aging (NIA)-Reagan staging, 8 of all 20 cases were reviewed.
MRI. T1-weighted volumetric MRI scans were acquired at 1.5 T (22 ϫ 16.5-cm field of view, 25°flip angle, 124 contiguous 1.6-mm-thick coronal slices). If a patient had more than one MRI, we used the closest scan of adequate quality to the time of first neurologic evaluation. Voxel-based morphometry (VBM) was used to compare the patterns of gray matter atrophy in the 5 subjects with aphasia and AD pathology, the 5 with aphasia and FTLD-U pathology, and the 10 with typical AD to the control group. An optimized method of VBM was applied using both customized templates and prior probability maps (priors), 30, 31 implemented using SPM2 (http://www.fil.ion.ucl.ac.uk/spm). To create the template, all scans, including those from the controls, the aphasia subjects with AD pathology, the aphasia subjects with FTLD-U pathology, and the typical AD subjects, were registered to the Montreal Neurological Institute (MNI) template using a 12dof affine transformation and segmented into gray matter (GM), white matter (WM), and CSF using MNI priors. GM images were normalized to the MNI GM prior using a nonlinear discrete cosine transformation (DCT). The normalization parameters were applied to the original whole head, and the images were segmented using the MNI priors. Average images were created of whole head, GM, WM, and CSF and were smoothed using an 8-mm full-width at half-maximum (FWHM) smoothing kernel. The average whole head image becomes the customized template, and the average GM, WM, and CSF images are then used as the customized prior probability maps for subsequent segmentations. All images were then registered to the customized whole brain template using a 12dof affine transformation and segmented using the customized priors. The GM images were normalized to the custom GM prior using a nonlinear DCT. The normalization parameters were then applied to the original whole head, and the images were segmented once again using the customized priors. All images were modulated and smoothed with an 8-mm FWHM smoothing kernel.
Two-sided t tests were used to assess the patterns of gray matter atrophy in each of the three disease groups compared with the control group. Gray matter differences were assessed after correction for multiple comparisons using the false discovery rate (p Ͻ 0.01). Direct statistical comparisons were also performed between each of the three disease groups. These between-group comparisons of gray matter differences were assessed at a threshold of p Ͻ 0.005 uncorrected for multiple comparisons because of the hypothesisdriven nature of these statistical tests. Only those clusters exceeding a voxel size of 100 were reported.
Statistical methods. Statistical analyses were performed
with JMP computer software (JMP Software, version 6.0.0, SAS Institute Inc., Cary, NC). Although multiple tests were performed, ␣ was set at 0.05 because of the small sample sizes and limited statistical power. Sex ratios were compared across the groups with the 2 test. Kruskal-Wallis tests were used to compare age at onset, age at death, age at scan, time from onset to scan, MMSE score and CDR sum of boxes score at the time of scan, and neuropsychometric scores across the subject groups. Because the control group was by definition cognitively normal, we excluded controls from tests of differences in cognitive scores. Pairwise testing was performed with Mann-Whitney U test.
RESULTS Demographic and clinical features.
All clinical, speech and language, and neuropsychological data reported were completed at the time of initial presentation. Demographics of all three groups are summarized in table 1. There was no difference in demographics across the three groups, including time from initial evaluation to time of death. Presenting features of the 5 subjects with aphasia and AD pathology are shown in table 2. All but 1 subject first presented for evaluation to a behavioral neurologist more than 2 years after onset. In all 5 subjects, the most prominent complaint was language impairment. By the time of presentation, however, all 5 had exhibited more widespread cognitive impairment. The majority had mild evidence of executive dysfunction. Two subjects were found to have features of the Gerstmann syndrome as finger agnosia, left-right confusion, and acalculia were documented in 2 subjects; 1 had difficulty with calculation very early into her disease course, although the language impairment was clearly the most prominent component of her illness. Although the diagnosis of PPA was considered, all 5 subjects were given a descriptive diagnosis of "aphasic dementia," i.e., aphasia with mild dementia, to highlight the prominence of the language component in the context of more widespread cognitive impairment. All 5 subjects with FTLD-U pathology presented with prominent aphasia, whereas all 10 subjects with typical AD and AD pathology presented with loss of episodic memory. None of the FTLD-U subjects were thought to have more widespread cognitive impairment by the evaluating physician, and hence all 5 were given a clinical diagnosis of PPA. In addition, in none of those with typical AD was aphasia a prominent feature at presentation. Language and speech. Language and speech findings of the 5 subjects with aphasia and AD pathology are summarized in table 3. In addition, we provide raw scores as supplemental data (table E-1 on the Neurology ® Web site at www.neurology. org). All subjects had language characteristics consistent with a diagnosis of aphasia, and all but Subject 2 (whose verbal comprehension was normal) had deficits in all tested language modalities. All had fluent narrative and conversational speech (i.e., no evidence of telegraphic/agrammatic speech or writing), with varying combinations and degrees of circumlocution, semantic or phonemic paraphasias, and a lack of specificity or paucity of specific content words. Some had pauses, hesitancy, or delayed initiation of verbal responses (Subjects 1, 4, 5) or infrequent paragrammatic errors (Subjects 2, 3). Although the aphasia was always predominant, all 5 subjects had subtle-to-obvious behaviors, or a profile of difficulty, that raised concerns about problems beyond the language domain (see table 2 for description). No subject had dysarthria or apraxia of speech.
Neuropsychology. The neuropsychological findings are summarized in table 4. Test scores were not statistically different across the three groups, with the exception of the test for Visual Reproduction Memory, 23 which was worse in the typical AD group compared with the FTLD-U group (p Ͻ 0.05). It was observed that subjects with aphasia and AD pathology had similar scores across the different cognitive domains tested when compared with the subjects with aphasia and FTLD-U pathology. The one exception was that the subjects with aphasia and FTLD-U pathology showed a trend to perform worse than those with aphasia and AD pathology on the Controlled Oral Word Association Test 20 (p ϭ 0.07). The pattern of language impairment for the subjects with aphasia and AD pathology was similar to the pattern of language impairment for the typical AD subjects, but the typical AD subjects had more severe memory impairment with a trend for a lower 30-minute delay and recognition memory scores on the Auditory Verbal Learning Test 23 (p ϭ 0.09 for both). Overall, the two groups of subjects with aphasia performed worse on the Boston Naming Test 19 compared with the subjects with typical AD (p ϭ 0.08); however, the subjects with typical AD performed worse on all tests of memory compared with the two groups of subjects with aphasia. There was also a trend for subjects with typical AD to have a worse perceptual organization index compared with subjects with aphasia and AD (p ϭ 0.07) and subjects with FTLD-U (p ϭ 0.05).
Pathologic findings. Grossly, all 20 subjects had mild-to-moderate generalized cerebral atrophy. In 2 subjects with aphasia and AD pathology and all 10 subjects with typical AD and AD pathology, there was moderate-to-severe medial temporal lobe atrophy. In all 15 subjects with AD pathology, there were widespread neocortical neurofibrillary tangles of Braak and Braak Stage VI. 29 There were also moderate-to-frequent neuritic and diffuse neocortical plaques in all 15 subjects with AD pathology; therefore, all 15 met NIA-Reagan criteria for high probability of AD. 8 The distribution of Alzheimer pathology was atypical in only 1 subject with aphasia and AD pathology with relative sparing of the hippocampus proper, which showed only mild neuronal loss, although there was a high density of neurofibrillary tangles. In 2 subjects with aphasia and AD pathology, there was gliosis in the globus pallidum. Two subjects with AD pathology, 1 with aphasia and 1 typical AD, had brainstem and limbic Lewy bodies consistent with transitional or limbic Lewy body disease. Immunohistochemistry with TDP-43 antibodies 28 was negative in all 15 subjects with AD pathology. The 5 subjects with FTLD-U were Braak Stage Յ II 29 and NIA-Reagan low probability of AD. 8 Semiquantitative analysis of regional neuronal loss across all three groups is shown in table 5.
MRI. The group of subjects with aphasia and AD pathology showed a predominantly left-sided pattern of temporoparietal gray matter loss compared with controls (figure, A). The gray matter loss in the temporal lobes included the left posterior inferior, middle, and superior temporal gyri, with remarkable sparing of the medial and anterior temporal pole. A small amount of gray matter loss was also identified in the frontal lobes. The right hemisphere showed little involvement, with areas of loss only identified in the posterior temporal lobe and parietal lobe. The group of subjects with aphasia and FTLD-U pathology also showed a left-sided pattern of atrophy predominantly involving the temporal lobe, including the amygdala, hippocampus, inferior and middle temporal gyri, and fusiform gyrus, compared with controls (figure, B). The regions of loss extended back into the posterior temporal lobe but did not involve the parietal lobes. Gray matter loss was also identified in the frontal lobes and anterior insula. Table 3 Speech-language characteristics based on formal speech-language examination at presentation* In contrast to both aphasic groups, the pattern of gray matter loss was bilateral in the subjects with clinical and pathologic AD compared with controls (figure, C). Gray matter loss particularly affected the medial temporal lobes and the temporoparietal association neocortex, although the posterior cingulate, frontal lobes, and posterior insula were also involved.
Direct statistical comparisons were also performed across the disease groups. The group of subjects with typical AD showed greater involvement of the right anterior hippocampus and amygdala than the aphasia subjects with AD pathology, and greater involvement of the posterior cingulate and parietal lobe than the subjects with FTLD-U. The aphasia subjects with AD pathology showed greater gray matter loss in regions of the left lateral frontal and parietal lobes compared with FTLD-U, and in the left lateral frontal and temporal lobes compared with typical AD. The FTLD-U group showed greater gray matter loss in the medial frontal lobes and anterior insula than both the aphasia with AD pathology group and the typical AD group, and greater anterior temporal lobe atrophy than the aphasia with typical AD pathology group. The coordinates of these regions are shown in table 6.
DISCUSSION
In this study, we demonstrate that when progressive aphasia is secondary to AD pa- Table 4 Neuropsychometric performances at presentation thology, the pattern of gray matter loss early in the disease course seems to be different from that of typical AD and also different from that of progressive aphasia with FTLD-U pathology. We also show that there is no secondary FTLD-U pathology. The medial temporal lobes were relatively spared on MRI at the time of presentation in patients who presented with progressive aphasia and AD pathology. 32 This should not be surpris-ing because episodic memory loss was not the most dominant feature of their illness at presentation. In contrast, our subjects with typical presentation of episodic memory loss and AD pathology showed severe involvement of the medial temporal lobe. In addition, we also found that the posterior cingulate region was heavily involved in our typical AD subjects as has been previously reported, 33, 34 but was relatively spared in our 5 aphasic subjects with AD pathology. Frontal lobe atrophy was observed in both groups, although the direct statistical comparison suggested that the frontal lobe loss was slightly more severe in the subjects with aphasia and AD pathology. Frontal lobe dysfunction was documented on presentation and confirmed with neuropsychometric testing in the aphasic group.
The pathology that most frequently underlies progressive fluent aphasia has been shown to be FTLD-U 2,10,35 or dementia lacking distinctive histology. 36 Our progressive aphasia subjects with AD pathology also had fluent speech output. Therefore, when a patient presents with a fluent aphasia (i.e., without apraxia of speech or agrammatism, or loss of syntax), the differential diagnosis should be first FTLD-U pathology and second AD. FTLD-U has replaced dementia lacking distinctive histology with the advent of ubiquitin and TDP-43 immunohistochemistry. 37, 38 We have shown that the pattern of atrophy early in the disease course is different when FTLD-U and AD pathology underlie progressive aphasia. In our subjects with FTLD-U pathology, there was left predominantly anterior temporal lobe atrophy with sparing of the parietal lobe. In contrast, in our progressive aphasic subjects with AD pathology, the temporoparietal association neocortex was heavily involved, with less involvement of the anterior temporal lobes. The temporoparietal atrophy in the aphasic subjects with AD pathology correlated with the fact that some of our subjects 
Data are reported as median (range). 0 ϭ no neuronal loss; 1 ϭ mild neuronal loss usual associated with microvacuolation (for the cortical sections); 2 ϭ moderate neuronal loss associated with thinning of the cortical ribbon (for the cortical sections); 3 ϭ end-stage neuronal loss associated with severe thinning of the cortical ribbon producing so called status spongiosis (for the cortical sections). Aphasia-AD ϭ subjects with progressive aphasia and Alzheimer disease pathology; aphasia-FTLD-U ϭ subjects with progressive aphasia and frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes pathology; typical AD ϭ subjects with a clinical and pathologic diagnosis of Alzheimer disease.
Figure
Patterns of gray matter loss identified by voxel-based morphometry in the aphasic subjects with AD pathology (A), aphasic subjects with frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes pathology (B), and subjects with clinical and pathologic AD (C), compared with controls (corrected for multiple comparisons, p Ͻ 0.01)
The results are shown both on a three-dimensional surface to illustrate the patterns of cortical gray matter loss and on a representative coronal slice (y ϭ Ϫ15) to illustrate the involvement of the hippocampus. AD ϭ Alzheimer disease.
had features of Gerstmann syndrome, which is typically associated with parietal lobe injury. Some medial frontal lobe atrophy was also observed in the aphasic subjects with FTLD-U. However, the frontal loss in more lateral regions was less severe than in the other two patient groups. This is interesting because the Controlled Word Association Test is a test of processing speed, and the FTLD-U group was the only group of the three that performed poorly on this test. 20 This suggests that the Controlled Word Association Test may be helpful in differentiating FTLD-U from AD as the cause of progressive fluent aphasia.
The anterior insula was also found to be involved in the subjects with fluent aphasia and FTLD-U pathology. The anterior insula has previously been implicated in the nonfluent variant of FTLD 4, 39 and particularly in apraxia of speech. 40 However, other studies have found no evidence for an association between insula atrophy and apraxia of speech 2 and have also found atrophy of the insula in fluent aphasia cases. 41 It is possible that apparent insula atrophy may simply reflect widening of the perisylvian fissure caused by atrophy in the frontal and temporal lobes, since anterior insula atrophy has also been observed in nonaphasic cases of FTLD. 42 The anatomic complexity of this region makes it difficult for VBM to accurately localize change.
All 5 subjects with progressive aphasia and AD had evidence of anomia, comprehension deficits, and fluent speech in ordinary conversation and on formal speech and language evaluation. None of our subjects had nonfluent speech, apraxia of speech, or agrammatism, as two studies reported. 10, 43 The clinical presentation in the 5 subjects with aphasia and AD pathology were thought to be somewhat atypical for PPA by the evaluating physicians, although PPA was still in the differential, because in all 5 subjects aphasia was not an isolated feature at the time of presentation. Neuropsychological examination also demonstrated more widespread cognitive impairment. Similar findings of more widespread cognitive impairment in patients who present with progressive fluent aphasia and are found to have AD pathology have been previously reported. 43 Language impairment, including confrontation naming 42 and sentence comprehension, 44 has been demonstrated in typical AD subjects. Our subjects with typical AD had formal testing of language, and performance in confrontation naming, semantic fluency, and sentence comprehension were below average, similar to our progressive aphasia with AD subjects. However, all of our typical AD subjects had a formal dementia evaluation by a behavioral neurologist who did not appreciate any obvious deficits in conversational speech with respect to prosody, melody, ar- Table 6 Regions of gray matter loss identified in the three subject groups when compared directly with each of the other two subject groups This table demonstrates the regions of the brain that showed greater gray matter loss in the subject group than in the comparison group. Voxel coordinates are in millimeters after transformation into standard Montreal Neurological Institute stereotactic space. Aphasia-AD ϭ subjects with progressive aphasia and Alzheimer disease pathology; aphasia-FTLD-U ϭ subjects with progressive aphasia and frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes pathology; typical AD ϭ subjects with a clinical and pathologic diagnosis of Alzheimer disease.
ticulation, grammatic form and qualitatively in the rate of word production, whereas our progressive aphasia with AD pathology subjects had obvious speech and language deficits on interview with a behavioral neurologist. This suggests one of two possibilities. First, our neuropsychological tests of language are not able to differentiate between primary language deficits and language deficits that may be occurring as a result of memory loss. Second, neuropsychological testing is more sensitive to language impairment in AD subjects than bedside cognitive or mental status testing. Hence, all subjects with AD, regardless of presenting features, have language impairment as suggested, 42, 44 but on bedside evaluation, the language impairment is being overshadowed by the memory loss. Therefore, it may not be the language deficits that make our aphasia with AD group stand out, but rather it is the absence of prominent episodic memory loss and visual perceptual deficits. One of the other interesting features of this study that requires more analysis was the similarity in the temporoparietal pattern of atrophy found in our progressive aphasia and AD pathology group, and the temporoparietal atrophy reported in logopenic PPA. 4 These similarities support the suggestion that AD pathology may underlie logopenic PPA. 4 This suggestion is also further strengthened by the fact that a possible 1 or 2 of our 5 subjects with AD pathology may meet criteria for logopenic PPA. 4 Although in our aphasia group with AD pathology we did not find any hippocampal volume loss as was reported with logopenic PPA, 4 this difference could be explained by the fact that the time from disease onset to scan was longer in that study, which suggests that their subjects were further along in their disease course.
The histopathologic findings in the AD cases presenting with aphasia were more widespread than the imaging findings. This suggests that the pathologic process spread beyond languagerelated regions and did not remain atypical with hippocampal sparing throughout the entire disease course. In addition, TDP-43 immunohistochemistry was negative, demonstrating that aphasia in our subjects with AD pathology was not caused by coexisting FTLD-U pathology. 28 It was important to perform TDP-43 analysis to rule out underlying FTLD-U pathology because ubiquitin immunohistochemistry is not specific and also highlights AD-type lesions.
